ARTICLE | Clinical News
Sorafenib regulatory update
September 19, 2005 7:00 AM UTC
FDA accepted for filing and granted Priority Review to an NDA for sorafenib to treat advanced renal cell carcinoma (RCC). The PDUFA date is undisclosed, but the companies hope to launch the product by January 2006. ...